Last updated: September 30, 2026
Sorbitan monolaurate, also known as sorbitan laurate or Span 20, is a nonionic, lipophilic surfactant used primarily as an emulsifier, wetting agent, and formulation stabilizer. Its pharmaceutical market is a specialty excipient niche rather than a separately reported drug market. Public companies generally disclose sorbitan monolaurate within broader excipient, surfactant, or pharmaceutical-ingredient revenue.
Demand is linked to oral, topical, cosmetic, veterinary, and food formulations. Growth is likely to be steady but limited by substitution from polysorbates, poloxamers, lecithin, glycerol esters, and newer solubilizing excipients. The commercial opportunity is strongest for high-purity, low-peroxide, traceable grades used in regulated formulations.
What is sorbitan monolaurate and how is it used in pharmaceuticals?
Sorbitan monolaurate is an ester of sorbitan and lauric acid. It is identified by CAS Registry Number 1338-39-2 and is commonly marketed under the trade name Span 20. The ingredient has a low hydrophilic-lipophilic balance, generally reported near 8.6, which makes it more suitable for water-in-oil emulsions and lipophilic formulation systems than for highly aqueous systems.
| Attribute |
Sorbitan monolaurate |
| Common names |
Sorbitan laurate, sorbitan monolaurate, Span 20 |
| CAS number |
1338-39-2 |
| Functional class |
Nonionic surfactant, emulsifier, wetting agent |
| Chemical source |
Sorbitol-derived sorbitan ester and lauric acid |
| HLB profile |
Approximately 8 to 9 |
| Main formulation role |
Emulsion stabilization, wetting, dispersion, co-emulsification |
| Typical competing excipients |
Polysorbates, poloxamers, lecithin, glyceryl esters, sucrose esters |
| Primary commercial grades |
Industrial, food, cosmetic, pharmaceutical, and high-purity grades |
Pharmaceutical applications include topical creams, ointments, emulsions, suspensions, soft gelatin capsules, tablets containing hydrophobic active ingredients, and selected parenteral or veterinary systems. Use depends on route, concentration, impurity profile, residual solvents, microbial control, and compatibility with the active pharmaceutical ingredient.
Sorbitan monolaurate is more often used in combination with a higher-HLB surfactant, such as polysorbate 20 or polysorbate 80, to create a balanced emulsifier system. The combination can improve droplet stabilization and reduce phase separation.
What is the market size for pharmaceutical-grade sorbitan monolaurate?
No reliable public source reports a standalone global market size for pharmaceutical-grade sorbitan monolaurate. Manufacturers typically combine sales of sorbitan esters with broader personal-care, food, pharmaceutical excipient, or specialty-ingredient categories.
The market is therefore best assessed through a bottom-up model:
- pharmaceutical and veterinary formulations using sorbitan esters;
- the percentage requiring monolaurate rather than monooleate or monostearate;
- the share purchased as pharmaceutical or high-purity grade;
- the premium paid for documentation, batch consistency, and regulatory support.
The pharmaceutical-grade segment is materially smaller than the total sorbitan ester market, which includes food, cosmetics, industrial emulsions, and animal-health products. Volume growth is likely to track formulation outsourcing, generic-drug production, topical dosage-form expansion, and demand for excipients with established regulatory histories.
The commercial market has four principal tiers:
| Market tier |
Buyer profile |
Value driver |
| Commodity grade |
Food, industrial, and nonregulated users |
Price and availability |
| Cosmetic grade |
Personal-care manufacturers |
Sensory performance and quality |
| Pharmaceutical grade |
Drug manufacturers and contract manufacturers |
GMP documentation and consistency |
| High-purity or specialty grade |
Sensitive formulations and regulated markets |
Low impurities, trace metals, peroxide control, and supply assurance |
Pharmaceutical-grade material commands a premium because manufacturers must qualify the supplier, establish specifications, and maintain change-control documentation. The price premium is not determined solely by chemical identity. It reflects manufacturing controls, testing, packaging, regulatory files, and supply continuity.
What is driving demand for sorbitan monolaurate?
Demand is supported by five factors.
Growth in topical and emulsion-based formulations
Sorbitan monolaurate is useful in creams, lotions, ointments, and emulsions where a low-HLB surfactant is required. Topical generics and dermatology products generally use established excipients because reformulation can trigger stability, bioequivalence, or regulatory work.
Continued use in softgel and lipid-based delivery systems
Lipid-based formulations require emulsifiers and wetting agents to disperse hydrophobic active ingredients. Sorbitan monolaurate can contribute to the interfacial system, although it competes with lecithin, polysorbates, and specialty lipid excipients.
Generic-drug and contract-manufacturing demand
Generic manufacturers generally favor excipients with established compendial or regulatory histories. Once an excipient is embedded in an approved formulation, replacement can require additional stability and performance testing.
Pharmaceutical outsourcing
Contract development and manufacturing organizations increasingly manufacture multiple dosage forms for different sponsors. This supports demand for broadly usable excipients, but it also increases purchasing leverage and price competition.
Demand for nonionic surfactants
Nonionic surfactants are often preferred over ionic materials because they are less sensitive to pH and electrolytes. Sorbitan monolaurate is useful when a formulation requires lipophilicity and relatively mild interfacial behavior.
What factors are limiting market growth?
Sorbitan monolaurate has several commercial limitations.
It has a lower HLB value than polysorbate 20 and is not a universal solubilizer for aqueous drug products. It may require a co-emulsifier. That increases formulation complexity and can make a single-surfactant alternative more attractive.
The material is also exposed to quality concerns associated with oxidation, residual free fatty acids, moisture, color, and batch-to-batch composition. These issues matter more in injectable and highly sensitive products than in topical products.
Pharmaceutical customers can also switch among sorbitan esters. Sorbitan monooleate, sorbitan monostearate, and sorbitan monopalmitate may provide better performance depending on the formulation’s oil phase, melting behavior, and target HLB.
Which companies supply pharmaceutical-grade sorbitan monolaurate?
The supply base includes global specialty-chemical companies, excipient manufacturers, regional producers, and distributors. Croda is a prominent supplier of pharmaceutical excipients and has marketed high-purity sorbitan ester products, including Span-branded materials. Other suppliers may sell sorbitan monolaurate through pharmaceutical, food, cosmetic, or laboratory channels.
Supplier qualification should distinguish between a catalog product and a drug-manufacturing grade. Relevant criteria include:
- GMP manufacturing and audit history;
- compendial compliance;
- residual solvent and elemental impurity controls;
- peroxide and acid-value specifications;
- microbial limits;
- excipient master-file support;
- change-notification commitments;
- dual-site or regional manufacturing;
- container-closure and storage controls.
The market has moderate supplier concentration at the high-purity end but broader competition at commodity grade. Buyers with validated formulations are less price-sensitive than new customers because changing suppliers can require comparability work and stability studies.
What is the FDA regulatory status of sorbitan monolaurate?
Sorbitan monolaurate is an excipient, not an active pharmaceutical ingredient. It does not receive independent FDA approval as a drug. Its regulatory acceptability depends on the dosage form, route of administration, concentration, product-specific safety assessment, and prior use.
The FDA Inactive Ingredient Database is the principal public reference for prior excipient use in approved drug products. Inclusion in the database indicates historical use, not universal approval for every route or concentration.[1]
Sorbitan monolaurate also has a food-additive identity as sorbitan laurate, commonly associated with E493 in the European food-additive system.[2] Food authorization does not automatically establish pharmaceutical suitability. Drug manufacturers still need pharmaceutical-grade specifications and product-specific justification.
Is sorbitan monolaurate listed in the Orange Book?
The Orange Book lists approved drug products and patent or exclusivity information for active pharmaceutical ingredients. Sorbitan monolaurate is not an active drug product and does not have an Orange Book patent listing as an ingredient.
Are there Paragraph IV challenges involving sorbitan monolaurate?
Paragraph IV litigation applies to abbreviated new drug applications challenging patents listed for a reference drug. Sorbitan monolaurate, as an excipient, does not have an independent Paragraph IV litigation pathway.
A generic product containing sorbitan monolaurate could face patent litigation involving the active ingredient, dosage form, formulation, method of treatment, or manufacturing process. The litigation would concern the finished drug product, not ownership of sorbitan monolaurate itself.
What patents protect sorbitan monolaurate?
The molecule is an old sorbitan fatty-acid ester and is not generally protected by a live, composition-of-matter patent in the manner of a recently discovered pharmaceutical active ingredient. Core patents covering sorbitan ester chemistry and broad emulsifier compositions are generally historical and likely expired in major jurisdictions.
The practical IP risks are located elsewhere:
| IP category |
Relevance to sorbitan monolaurate |
| Composition of matter |
Generally low risk because the compound is established |
| Manufacturing process |
Possible protection for purification, esterification, or low-impurity production |
| Formulation |
Possible protection when used in a specific drug-delivery system |
| Method of use |
Possible for a particular therapeutic or delivery application |
| Particle or droplet engineering |
Possible where the excipient is part of a defined dispersion |
| Trade secrets |
Important for reaction conditions, purification, and quality control |
| Supplier know-how |
Important for low-peroxide and narrow-specification grades |
A freedom-to-operate review should therefore search claims combining sorbitan monolaurate with a specific active ingredient, dosage form, route, ratio, particle-size distribution, or manufacturing step. Searching only the excipient name will understate relevant formulation risk.
What formulation patents involve sorbitan monolaurate?
Formulation patents may claim:
- oil-in-water or water-in-oil emulsions;
- topical delivery systems;
- sustained-release lipid matrices;
- softgel fills;
- nanoparticle or microparticle dispersions;
- vaccine adjuvant systems;
- agricultural or veterinary delivery systems;
- combinations of sorbitan monolaurate with polysorbates or lecithin.
The highest commercial risk occurs when the excipient is used in a narrow formulation claim tied to a commercially important active ingredient. A supplier selling the excipient as a raw material usually faces less risk than a drug manufacturer using it in a patented finished product.
How strong is the patent estate for sorbitan monolaurate?
The standalone patent estate is weak because the chemical entity is old, widely known, and available from multiple suppliers. The stronger protection is downstream.
| Patent layer |
Relative strength |
| Basic sorbitan monolaurate molecule |
Low |
| Broad sorbitan ester use |
Low to moderate, depending on claim age |
| High-purity manufacturing process |
Moderate |
| Specific pharmaceutical formulation |
Moderate to strong |
| Active-ingredient combination |
Potentially strong |
| Supplier specifications and process know-how |
Non-patent, commercially important |
Patent expiry does not eliminate commercial barriers. A customer may remain with an incumbent supplier because of qualification costs, quality history, and regulatory documentation.
What manufacturing and supply-chain risks affect sorbitan monolaurate?
Sorbitan monolaurate is manufactured from sorbitol-derived intermediates and lauric acid. Its economics are influenced by:
- lauric acid prices;
- coconut and palm-kernel oil markets;
- sorbitol availability;
- energy and transportation costs;
- plant utilization;
- purification requirements;
- packaging and storage conditions;
- regional regulatory requirements.
Lauric acid is particularly relevant because supply is linked to tropical-oil markets. Supply interruptions can affect both cost and lead times. Pharmaceutical customers may carry more inventory than cosmetic or food customers because requalification can be costly.
Manufacturing barriers are moderate rather than prohibitive. The chemistry is established, but pharmaceutical-grade production requires controlled impurity profiles, validated testing, documented change control, and consistent physical properties.
How does sorbitan monolaurate compare with competing excipients?
| Excipient |
Relative advantage |
Relative limitation |
| Sorbitan monolaurate |
Lipophilic emulsification and established use |
Limited aqueous solubilization |
| Polysorbate 20 |
Stronger aqueous compatibility and broad use |
Oxidation and degradation concerns |
| Polysorbate 80 |
Broad biologic and emulsion use |
Peroxide, hydrolysis, and impurity concerns |
| Sorbitan monooleate |
Useful for oil-based systems |
Different melting and oxidation profile |
| Sorbitan monostearate |
Strong emulsion and consistency properties |
Less suitable for some low-temperature systems |
| Lecithin |
Natural-source positioning and broad lipid compatibility |
Variable composition and oxidation risk |
| Poloxamer 188 |
Useful in biologics and aqueous systems |
Higher cost and different formulation behavior |
| Sucrose esters |
Tunable HLB and food acceptance |
Higher cost and narrower supplier base |
Sorbitan monolaurate is most competitive when the formulation requires a lipophilic, nonionic emulsifier and the manufacturer values established supply over maximum aqueous solubilization.
What is the financial trajectory for sorbitan monolaurate suppliers?
Public financial reporting does not isolate sorbitan monolaurate revenue. The financial trajectory is therefore best described as a specialty-excipient growth profile:
- volume growth: low to moderate;
- price growth: dependent on feedstocks and grade;
- margin potential: higher for pharmaceutical-grade material than commodity grade;
- customer retention: relatively strong after formulation qualification;
- substitution risk: moderate;
- regulatory burden: rising for high-purity applications;
- cyclicality: lower in pharmaceuticals than in cosmetics and industrial markets.
Revenue growth is likely to come more from grade upgrades, geographic expansion, and formulation support than from dramatic volume increases. Suppliers with pharmaceutical documentation, multiple manufacturing locations, and technical support should capture more value than producers competing solely on price.
The most exposed suppliers are those selling undifferentiated material into food, cosmetics, and industrial markets. Their results are more sensitive to lauric-acid costs and customer inventory cycles.
What generic entry risks exist for products using sorbitan monolaurate?
The excipient itself is not the principal entry barrier. Generic entry risk depends on the finished product’s active ingredient, dosage form, formulation patent, regulatory pathway, and manufacturing complexity.
For a generic drug using sorbitan monolaurate, relevant risks include:
- formulation patents covering the emulsion or lipid system;
- method-of-use patents;
- bioequivalence difficulty for complex topical or modified-release products;
- sensitivity to excipient grade and supplier changes;
- limited availability of validated pharmaceutical-grade material;
- patent claims directed to ratios of sorbitan monolaurate and co-emulsifiers.
For standard immediate-release tablets or conventional topical products, the excipient is generally a modest barrier. For complex emulsions, softgels, injectables, and delivery systems, the formulation and manufacturing process can materially delay entry.
What licensing deals and settlement agreements involve sorbitan monolaurate?
There is no established public record of major licensing agreements centered solely on sorbitan monolaurate as an excipient. Licensing and settlement activity is more likely to concern a finished pharmaceutical formulation in which the excipient is one component.
Confidential supply agreements are commercially more relevant than public patent licenses. These may include minimum-volume commitments, regional exclusivity, quality agreements, technical-support obligations, and change-control provisions.
What geographic markets offer the strongest opportunity?
North America and Europe offer the highest value per kilogram because pharmaceutical customers pay for regulatory support and documentation. Asia-Pacific offers the strongest volume opportunity because of generic-drug manufacturing, contract manufacturing, and expanding formulation capacity.
| Region |
Commercial profile |
| United States |
High documentation standards and strong generic-manufacturing base |
| European Union |
Strict quality expectations and established excipient regulation |
| China |
Large manufacturing base and growing domestic pharmaceutical demand |
| India |
Strong generic and contract-development ecosystem |
| Japan and South Korea |
High quality requirements and technically demanding customers |
| Latin America |
Smaller specialty market with selected import dependence |
Geographic expansion requires more than distribution. Suppliers must address local registration expectations, language-specific documentation, import controls, and customer audits.
Key Takeaways
- Sorbitan monolaurate is a mature nonionic surfactant used mainly as a lipophilic emulsifier and wetting agent.
- Its pharmaceutical market is a specialty niche and is not separately reported by most public companies.
- Demand is linked to topical products, lipid-based formulations, softgels, generics, and contract manufacturing.
- The compound has limited standalone patent protection because its chemistry is old and broadly established.
- Commercial IP risk is concentrated in finished formulations, manufacturing processes, and active-ingredient combinations.
- FDA and Orange Book pathways apply to finished drugs, not to sorbitan monolaurate as an excipient.
- High-purity pharmaceutical grades can generate better margins than commodity material because qualification and documentation create switching costs.
- The principal financial risks are substitution, feedstock volatility, supplier concentration at the high-purity end, and formulation-specific demand.
- Asia-Pacific offers the strongest volume growth, while North America and Europe offer higher regulatory-value premiums.
- The most attractive strategy is to sell documented, low-impurity, GMP-supported grades rather than compete solely on chemical identity or price.
FAQs
Is sorbitan monolaurate the same as polysorbate 20?
No. Sorbitan monolaurate is a lipophilic sorbitan ester with a lower HLB value. Polysorbate 20 is a polyoxyethylene derivative with substantially greater hydrophilicity and different formulation behavior.
Can sorbitan monolaurate be used in injectable medicines?
It may be considered in selected parenteral formulations, but use depends on route, concentration, impurity profile, toxicology, and product-specific regulatory justification. Prior use in another dosage form does not establish injectable acceptability.
Does sorbitan monolaurate have a USP monograph?
Availability of a USP-NF monograph must be confirmed against the current edition and applicable supplier specification. A supplier’s pharmaceutical grade may also rely on internal specifications and regulatory documentation beyond compendial identity testing.[3]
Is sorbitan monolaurate suitable for biologic drugs?
It can be relevant to selected emulsions or delivery systems, but polysorbates and poloxamers are more established in many biologic formulations. Oxidation, hydrolysis, protein interaction, and container compatibility require product-specific evaluation.
What is the main investment risk in the sorbitan monolaurate market?
The main risk is limited category visibility. Suppliers rarely report the ingredient separately, so investors must evaluate broader excipient-segment performance, customer concentration, feedstock exposure, manufacturing qualification, and the share of pharmaceutical-grade revenue.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
European Commission. (n.d.). EU food additives database. https://food.ec.europa.eu/safety/food-improvement-agents/additives/database_en
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
-
Croda International Plc. (2023). Annual report and accounts 2023. https://www.croda.com
-
European Food Safety Authority. (2017). Re-evaluation of sorbitan esters as food additives. EFSA Journal. https://www.efsa.europa.eu
